August 30, 2014 7:25 AM ET

Pharmaceuticals

Company Overview of ImQuest Pharmaceuticals, Inc

Company Overview

ImQuest Pharmaceuticals, Inc. develops drugs for the treatment of infectious diseases, cancer, and inflammation. The company focuses on various drug development programs, such as therapies for the treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), and cancer, as well as on topical microbicides for the prevention of transmission of HIV and other sexually transmitted infections. It develops a vaginal gel for the prevention of HIV transmission to women. The company was founded in 2005 and is based in Frederick, Maryland.

7340 Executive Way

Suite R

Frederick, MD 21704

United States

Founded in 2005

Phone:

301-696-0274

Fax:

301-696-0381

Key Executives for ImQuest Pharmaceuticals, Inc

President and Chief Scientific Officer
Director of Biological Sciences and Director
Compensation as of Fiscal Year 2014.

ImQuest Pharmaceuticals, Inc Key Developments

ImQuest Pharmaceuticals Receives FDA Approval to Initiate Clinical Trials of Vaginal Gel for the Prevention of HIV Transmission to Women

ImQuest Pharmaceuticals was recently notified by the US Food and Drug Administration of the approval of its Investigational New Drug (IND) application to study the safety in Phase 1 clinical trials of its vaginal gel containing the nonnucleoside reverse transcriptase HIV Inhibitor IQP-0528. Preclinical studies have shown that IQP-0528 is highly effective against virus strains found throughout the world, prevents HIV transmission in cultured cells, causes sterilization of cultures infected with HIV, and acts in concert with other approved HIV drugs to inhibit the virus. The IQP-0528 vaginal gel is being developed with the goal of preventing the sexual transmission of HIV to women throughout the world. ImQuest plans to evaluate the safety of the IQP-0528 vaginal gel in a Phase I clinical trial at medical centers in the United States and expects to begin recruiting women for the trial by the end of the year. This marks the company's first product to receive FDA approval for clinical trials. ImQuest Pharmaceuticals developed the HIV inhibitor in partnership with Samjin Pharmaceutical Co. Ltd. of Seoul Korea. Preclinical testing was conducted by ImQuest BioSciences of Frederick, Maryland using the company's newly launched ImQuestSUCCESS(TM) platform, which enables the rapid identification of drug candidates with a high probability of clinical success early in the discovery and development process. Development of ImQuest's prevention products has been supported in part by the National Institutes of Health and the International Partnership for Microbicides, which is funded by The Bill and Melinda Gates Foundation and The United States Agency for International Development (USAID). The company plans to submit a second IND to the FDA for approval to test IQP-0528 in a DuoGel(TM) formulation for protection of both vaginal and rectal virus transmission to men and women early next year -- a product which will represent a major advancement for microbicide products in the pharmaceutical industry.

Similar Private Companies By Industry

Company Name Region
Saladax Biomedical, Inc. United States
Quanticel Pharmaceuticals, Inc. United States
Hibernaid, Inc. United States
Cody Laboratories, Inc. United States
Meridian Medical Technologies, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ImQuest Pharmaceuticals, Inc, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.